Selective Laser Trabeculoplasty – The First-line Treatment For Open-Aangle Glaucoma?!
DOI:
https://doi.org/10.61699/cjmps-v1-i5-6-p1-12Keywords:
intraocular pressure, selective laser trabeculoplasty, pseudoexfoliation glaucomaAbstract
The purpose of this nonrandomized study conducted at the Eye Clinic "Akhali Mzera" between October 2011 and November 2022 was to evaluate the intraocular pressure (IOP) reduction and side effects following selective laser trabeculoplasty (SLT). A total of 867 eyes of 558 patients with early to moderate primary open-angle glaucoma (POAG) or pseudoexfoliation glaucoma (PXG) phakic and pseudophakic were included in the study. The patients were treated with laser as primary therapy or adjunct laser with medication. The mean age of the study participants was 54.3 ± 5.2 years (range, 40 to 78 years) and 362 (64.9%) were males. The glaucoma diagnosis was POAG in 726 (83.7%) eyes and PXG in 141 (16.3%) eyes. Diabetes mellitus in 8% and systemic hypertension in 30% were noted. 736 eyes (84.9%) were on medications, and 130 (14.9%) eyes were treated with laser as primary therapy. Overall, the mean IOP after SLT was 17.8 ± 3.2mmHg, 18.8 ± 2.3 mmHg, and 23.4 ± 2.5 mmHg in the 12th month, 24th month, and 36th month respectively. About 20% of patients with POAG lost efficacy in 18 months post-treatment and in these eyes, the second SLT procedure was more effective than the first one. The number of drugs reduced from an average of 1.3 to an average of 1.0 was statistically significant with the inter-eye correlation. Those patients who were treated with laser as primary therapy with a baseline IOP of 25.4 mmHg ±2.9 mmHg had IOP reduction of 7.5 ± 3.1 mmHg at the last visit, and those who were on antiglaucoma medication with baseline IOP 23.9 ± 2.2 mmHg had IOP reduction of 4.8 ± 2.8 mmHg. IOP reduction at the last visit between POAG, and PXG was 6.5 mmHg and 7.9 mmHg, respectively. It was concluded that SLT is a safe and innovative technology that uses lasers to target only certain cells of the trabecular meshwork of the eye.
References
Alexander RA, Grierson I, Church WH. The effect of argon laser trabeculoplasty upon the normal human trabecular meshwork. Graefes Arch Clin Exp Ophthalmol. 1989;227(1):72-77. doi:10.1007/BF02169830
McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye (Lond). 2014;28(3):249-258. doi:10.1038/eye.2013.267
Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121(5):473-483. doi:10.1016/s0002-9394(14)75421-2
Bylsma SS, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988;106(4):544-547. doi:10.1001/archopht.1988.01060130590044
Fan N, Wang P, Tang L, Liu X. Ocular Blood Flow and Normal Tension Glaucoma. Biomed Res Int. 2015;2015:308505. doi:10.1155/2015/308505
Garg A, Gazzard G. Selective laser trabeculoplasty: past, present, and future [published correction appears in Eye (Lond). 2020 Aug;34(8):1487]. Eye (Lond). 2018;32(5):863-876. doi:10.1038/eye.2017.273
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial [published correction appears in Lancet. 2019 Jul 6;394(10192):e1]. Lancet. 2019;393(10180):1505-1516. doi:10.1016/S0140-6736(18)32213-X
The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990;97(11):1403-1413.
The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120(1):10-22. doi:10.1016/s0002-9394(14)73754-7
The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120(6):718-731. doi:10.1016/s0002-9394(14)72725-4
Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105(11):2099-2104. doi:10.1016/S0161-6420(98)91133-2
Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773-779. doi:10.1016/s0161-6420(00)00660-6
Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113-1124. doi:10.1056/NEJMra0804630
Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60(4):359-371. doi:10.1016/s0014-4835(05)80093-4
Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105(11):2082-2090. doi:10.1016/S0161-6420(98)91129-0]
Ma A, Yu SWY, Wong JKW. Micropulse laser for the treatment of glaucoma: A literature review. Surv Ophthalmol. 2019;64(4):486-497. doi:10.1016/j.survophthal.2019.01.001
Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003;121(7):957-960. doi:10.1001/archopht.121.7.957
Shaw E, Gupta P. Laser Trabeculoplasty. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 10, 2023.
Sayin N, Alkin Z, Ozkaya A, et al. Efficacy of selective laser trabeculoplasty in medically uncontrolled glaucoma. ISRN Ophthalmol. 2013;2013:975281. Published 2013 Jan 8. doi:10.1155/2013/975281
Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090-1095. doi:10.1001/archopht.1991.01080080050026
Thonginnetra O, Greenstein VC, Chu D, Liebmann JM, Ritch R, Hood DC. Normal versus high tension glaucoma: a comparison of functional and structural defects. J Glaucoma. 2010;19(3):151-157. doi:10.1097/IJG.0b013e318193c45c
Thumann G, Sorgente N, Kropp M, Jonescu-Cuypers C.- P. Tolbutamide Eye Drops Increase Aqueous Humor Outflow and Lower Intraocular Pressure: A Proof of Concept for Glaucoma Treatment. Journal of Ophthalmology and Research. 2021; 4: 114-127
Töteberg-Harms M, Meier-Gibbons F. Is laser trabeculoplasty the new star in glaucoma treatment?. Curr Opin Ophthalmol. 2021;32(2):141-147. doi:10.1097/ICU.0000000000000732
Vohra R, Tsai JC, Kolko M. The role of inflammation in the pathogenesis of glaucoma. Surv Ophthalmol. 2013;58(4):311-320. doi:10.1016/j.survophthal.2012.08.010
Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979;97(2):319-322. doi:10.1001/archopht.1979.01020010165017
Wong MO, Lee JW, Choy BN, Chan JC, Lai JS. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015;60(1):36-50. doi:10.1016/j.survophthal.2014.06.006
Zhou R, Sun Y, Chen H, Sha S, He M, Wang W. Laser Trabeculoplasty for Open-Angle Glaucoma: A Systematic Review and Network Meta-Analysis. Am J Ophthalmol. 2021;229:301-313. doi:10.1016/j.ajo.2020.07.046
